Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EW 
Edwards Lifesciences Corp (EW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: EW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
32 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $80.87
Year Target Price $80.87
| 10 | Strong Buy |
| 4 | Buy |
| 17 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.44% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 45.88B USD | Price to earnings Ratio 32.32 | 1Y Target Price 81.01 |
Price to earnings Ratio 32.32 | 1Y Target Price 81.01 | ||
Volume (30-day avg) - | Beta 1.12 | 52 Weeks Range 58.93 - 95.25 | Updated Date 06/29/2025 |
52 Weeks Range 58.93 - 95.25 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 75.71% | Operating Margin (TTM) 29.02% |
Management Effectiveness
Return on Assets (TTM) 8.42% | Return on Equity (TTM) 16.51% |
Valuation
Trailing PE 32.32 | Forward PE 32.05 | Enterprise Value 42678886000 | Price to Sales(TTM) 8.31 |
Enterprise Value 42678886000 | Price to Sales(TTM) 8.31 | ||
Enterprise Value to Revenue 7.73 | Enterprise Value to EBITDA 24.07 | Shares Outstanding 586600000 | Shares Floating 580552154 |
Shares Outstanding 586600000 | Shares Floating 580552154 | ||
Percent Insiders 0.92 | Percent Institutions 89.48 |
Analyst Ratings
Rating 3.69 | Target Price 80.87 | Buy 4 | Strong Buy 10 |
Buy 4 | Strong Buy 10 | ||
Hold 17 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Edwards Lifesciences Corp
Company Overview
History and Background
Edwards Lifesciences Corp. was founded in 1958 by Miles 'Lowell' Edwards and Albert Starr. Initially focused on developing the Starr-Edwards mitral valve, the company pioneered the field of heart valve replacement. Over the decades, it has expanded its portfolio to include hemodynamic monitoring and advanced surgical technologies.
Core Business Areas
- Transcatheter Aortic Valve Replacement (TAVR): Develops and markets minimally invasive heart valve replacement technologies, specifically transcatheter aortic valves. This segment is a major revenue driver.
- Surgical Structural Heart: Offers surgical heart valve repair and replacement products, as well as related technologies. Provides options for patients unsuitable for TAVR.
- Critical Care: Provides hemodynamic monitoring systems and related products that allow clinicians to assess a patient's cardiovascular function and make informed decisions about treatment.
- Transcatheter Mitral and Tricuspid Therapies (TMTT): Focuses on developing transcatheter therapies for mitral and tricuspid valve disease. This is a growth-oriented segment.
Leadership and Structure
The company is led by CEO Bernard J. Zovighian. Edwards Lifesciences operates with a corporate structure that includes executive leadership, business segment heads, and functional departments.
Top Products and Market Share
Key Offerings
- Competitors: Medtronic (MDT), Abbott (ABT)
- SAPIEN 3 TAVR Valve: A leading transcatheter aortic valve, offering a minimally invasive alternative to open-heart surgery for aortic valve replacement. Estimated TAVR market share around 50% with competitors such as Medtronic (MDT) and Abbott (ABT). Estimated to have generated >$4 Billion USD Revenue in 2023.
- Competitors: Medtronic (MDT), Abbott (ABT), Boston Scientific (BSX)
- Inspiration Resilia Aortic Valve: A surgical aortic valve using RESILIA tissue, designed for durability. Market share is smaller than TAVR but is a established product line. Competitors include Medtronic (MDT), Abbott (ABT), and Boston Scientific (BSX).
- Competitors: ICU Medical (ICUI), Philips (PHG)
- HemoSphere Advanced Monitoring Platform: A platform for hemodynamic monitoring in critical care settings. Competitors include ICU Medical (ICUI) and Philips (PHG)
Market Dynamics
Industry Overview
The global cardiovascular device market is experiencing growth driven by aging populations, increasing prevalence of heart disease, and technological advancements in minimally invasive procedures.
Positioning
Edwards Lifesciences is a market leader in heart valve replacement, particularly in the TAVR segment. Its competitive advantages include a strong brand reputation, extensive clinical data supporting its products, and a robust innovation pipeline.
Total Addressable Market (TAM)
The global heart valve market is projected to reach $15-20 billion by 2028. Edwards is a key player, positioned to benefit from the increasing adoption of minimally invasive procedures.
Upturn SWOT Analysis
Strengths
- Market leader in TAVR
- Strong brand reputation
- Extensive clinical data
- Robust innovation pipeline
- Strong global presence
- Patented Technologies
Weaknesses
- High reliance on TAVR segment
- Susceptibility to regulatory changes
- Competitive pressure from established players
- Relatively high product pricing may limit accessibility in some markets
Opportunities
- Expanding TAVR indications to younger patients
- Developing new transcatheter therapies for mitral and tricuspid valves
- Entering emerging markets
- Partnerships and acquisitions to expand product portfolio
Threats
- Increasing competition in TAVR market
- Price erosion due to competition and healthcare cost containment
- Technological disruptions from new entrants
- Adverse regulatory changes or clinical trial outcomes
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
Edwards Lifesciences maintains a leading position due to its pioneering history and focus on innovation. They continue to grow their existing segments with new product offerings.
Major Acquisitions
ValCare Medical
- Year: 2020
- Acquisition Price (USD millions): 50
- Strategic Rationale: Expanded the company's transcatheter mitral and tricuspid therapy portfolio.
Growth Trajectory and Initiatives
Historical Growth: Edwards has experienced significant growth in recent years, primarily driven by the increasing adoption of TAVR and its expansion into new markets. ~10-15% Growth over past 5 years.
Future Projections: Analysts project continued growth for Edwards, driven by expanding TAVR indications, new product launches in TMTT, and expansion into emerging markets. Expected to be at least 10% growth for the next 3 years.
Recent Initiatives: Recent initiatives include the development of new TAVR platforms, expansion of the TMTT portfolio, and strategic acquisitions to enhance its product offerings.
Summary
Edwards Lifesciences is a strong company with a leadership position in the growing TAVR market. Its strengths lie in its innovative products, clinical expertise, and global presence. The company should be wary of increasing competition and regulatory changes. Overall, Edwards Lifesciences demonstrates strong growth potential in the cardiovascular device market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Investor Presentations, Industry Reports, Analyst Estimates.
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edwards Lifesciences Corp
Exchange NYSE | Headquaters Irvine, CA, United States | ||
IPO Launch date 2000-03-27 | CEO & Director Mr. Bernard J. Zovighian | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15800 | Website https://www.edwards.com |
Full time employees 15800 | Website https://www.edwards.com | ||
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.